Evidence map›Paper›PMID 40094073›Full record

ArticleCancer innovation2025

Investigating the Mechanism of IFN-γ-Inducible Lysosomal Thiol Reductase-Mediated Inhibition of Breast Cancer Cell Proliferation.

Qin Liu, Xiaoning Yuan, Youcheng Shao, Xiaoqing Guan, Kaixiang Feng, Mengfei Chu, Le Chen, Hui Li, Hanhui Liu, Jingwei Zhang and 2 more

Abstract read
In one paragraph

Article in Cancer innovation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Qin LiuDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.ORCID 0009-0000-1919-8027
Xiaoning YuanDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Youcheng ShaoDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Xiaoqing GuanDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Kaixiang FengDepartment of Breast and Thyroid Surgery Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center Wuhan Hubei China.ORCID 0000-0001-7831-3072
Mengfei ChuDepartment of Human Anatomy TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Le ChenDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Hui LiDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Hanhui LiuDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Jingwei ZhangDepartment of Breast and Thyroid Surgery Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center Wuhan Hubei China.ORCID 0000-0002-4188-2236
Yihao TianDepartment of Human Anatomy TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.
Lei WeiDepartment of Pathology and Pathophysiology Hubei Provincial Key Laboratory of Developmentally Originated Disease, TaiKang Medical School (School of Basic Medical Sciences), Wuhan University Wuhan Hubei China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Breast cancer has become a severe threat to human health, making it imperative to identify effective drugs and therapeutic targets. Methods: Various molecular biology experiments, such as western blot analysis, cytologic effect, co-immunoprecipitation, and immunofluorescence assays, as well as a nude mouse xenograft tumor model, were used to comprehensively analyze the impact of gamma-interferon-inducible lysosomal thiol reductase (GILT) on the malignant phenotype of breast cancer cells. This work was performed to examine GILT expression levels and explore the potential mechanism in breast cancer. Results: GILT protein expression levels were significantly lower in breast cancer cells than in normal breast epithelial cells. Overexpressing GILT inhibited breast cancer cell proliferation and migration and slowed tumor growth. GILT inhibited the interaction between the MYC and WDR5 transcription complex and played a tumor-suppressive role. The MYC/WDR5 transcription complex inhibitor OICR-9429 could synergize with GILT to inhibit breast cancer cell proliferation. Conclusion: This study reveals a potential mechanism by which GILT can slow breast cancer growth, as well as identifying the possible clinical application value of small molecule inhibitor OICR-9429. These data collectively provide novel treatment strategies for breast cancer therapy.

Indexed as

breast cancerIFN‐γ‐inducible lysosomal thiol reductaseMYCOICR‐9429WDR5

Identifiers

PMID40094073
PMCPMC11909800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.